Palonosetron: An evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy

Tumori

Volumn 98, Issue 3, 2012, Pages 279-286

  Celio, Luigi ^a   Agustoni, Francesco ^a   Testa, Isabella ^a   Dotti, Katia ^a   De Braud, Filippo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anti emesis guidelines; CINV; Moderately emetogenic chemotherapy; Palonosetron

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; FLUOROURACIL; FOLINIC ACID; GRANISETRON; IRINOTECAN; NEUROKININ 1 RECEPTOR; ONDANSETRON; OXALIPLATIN; PALONOSETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; CONSTIPATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; INFUSIONS, INTRAVENOUS; INTERNATIONAL COOPERATION; ISOQUINOLINES; MORPHOLINES; NAUSEA; PRACTICE GUIDELINES AS TOPIC; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, NEUROKININ-1; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; SIGNAL TRANSDUCTION; VOMITING;

EID: 84867080087     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161209800301     Document Type: Review

References (37)

1. Nevidjon B, Chaudhary R: Controlling emesis: evolving challenges, novel strategies. J Support Oncol, 8 (suppl 2): 1-10, 2010.
2. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol, 29: 4189-4198, 2011.
3. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 21 (suppl 5): v232-v243, 2010.
4. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Antiemesis, version 1.2012. Available at http://www.nccn.org/ professionals/physician-gls/ PDF/antiemesis.pdf; accessed September 27, 2011.
5. Hesketh PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med, 358: 2482-2494, 2008.
6. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer, 100: 2261-2268, 2004. (Pubitemid 38580348)
7. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J: Delayed nausea and vomiting continue to reduce patient's quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol, 24: 4472-4478, 2006. (Pubitemid 46630986)
8. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H: Chemotherapy-induced nausea and vomiting incidence and impact on patient quality of life at community oncology settings. Support Care Cancer, 15: 497-503, 2007. (Pubitemid 46570778)
9. Wickham R: Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use. J Support Oncol, 8 (suppl 1): 10-15, 2010.
10. Grunberg SM: Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol, 18: 233-240, 2007.
11. 3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer, 15: 1023-1033, 2007.
12. Geling O, Eichler HG: Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic reevaluation of clinical evidence and drug cost implications. J Clin Oncol, 23: 1289-1294, 2005. (Pubitemid 46202287)
13. Celio L, Denaro A, Canova S, Gevorgyan A, Bajetta E: Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori, 94: 447-452, 2008.
14. 3 receptors, in vitro. Br J Pharmacol, 114: 851-859, 1995.
15. 3 receptor antagonist for chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother, 11: 1003-1014, 2010.
16. 3 receptor. Anesth Analg, 107: 469-478, 2008.
17. 3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol, 626: 193-199, 2010.
18. Higa GM, Auber ML, Altaha R, Kurian S, Hobbs G: Concordance between substance P levels and antiemetic guidelines. J Support Oncol, 7: 138-142, 2009.
19. Hu WP, You XH, Guan BC, Ru LQ, Chen JG, Li ZW: Substance P potentiates 5-HT3 receptor-mediated current in rat trigeminal ganglion neurons. Neurosci Lett, 365: 147-152, 2004.
20. Minami M, Endo T, Yokota H, Ogawa T, Nemoto M, Hamaue N, Hirafuji M, Yoshioka M, Nagahisa A, Andrews PL: Effects of CP-99,994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT3 receptors. Eur J Pharmacol, 428: 215-220, 2001. (Pubitemid 33000143)
21. 3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Experimen Therap, 335: 362-368, 2010.
22. Gralla R, Lichinitser M, Van der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol, 14: 1570-1577, 2003. (Pubitemid 37304615)
23. 3 receptor anatagonist. Results of a phase III, single-dose trial versus dolasetron. Cancer, 98: 2473-2482, 2003.
24. Aapro M, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol, 17: 1441-1449, 2006. (Pubitemid 44400384)
25. Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegorotti B: Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer, 19: 823-832, 2011.
26. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative phase III trial. Lancet Oncol, 10: 115-124, 2009.
27. Maemondo M, Masuda N, Sekine I, Kubota K, Segawa Y, Shibuya M, Imamura F, Katakami N, Hida T, Takeo S: A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann Oncol, 20: 1860-1866, 2009.
28. Segawa Y, Aogi K, Inoue K, Sano M, Sekine I, Tokuda Y, Isobe H, Ogura T, Tsuboi M, Atagi S: A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. Ann Oncol, 20: 1874-1880, 2009.
29. Likun Z, Xiang J, Yi B, Xin D, Tao ZL: A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist, 16: 207-216, 2011.
30. Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA: Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J Support Oncol, 4: 467-471, 2006. (Pubitemid 44698155)
31. Giuliani F, Cilenti G, Nugnes I, Maiello E, Di Bisceglie M, Lorusso V, Adamo V, Colucci G: Palonosetron for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic adjuvant folfox-4 regimen in colorectal cancer (CRC) patients: a phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Eur J Cancer Supplements, 6: 102-106, 2008.
32. Brugnatelli S, Gattoni E, Grasso D, Rossetti F, Perrone T, Danova M: Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients. Tumori, 97: 362-366, 2011.
33. Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E, Fabi A, Capobianco AM, Isa L, Cavanna L, Bertolini A, Bichisao E, Bajetta E: Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multi center, phase III trial. Support Care Cancer, 19: 1217-1225, 2011.
34. Aapro M, Fabi A, Nolè F, Medici M, Steger G, Bachmann C, Roncoroni S, Roila F: Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol, 21:1083-1088, 2010.
35. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol, 23: 2822-2830, 2005. (Pubitemid 46179473)
36. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF: Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer, 94: 1011-1015, 2006.
37. Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M: Effectiveness of a singleday three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer, 17: 589-594, 2009.